- Home
- MDCX vs CALC Comparison
MDCX vs CALC Comparison
Compare MDCX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | CALC |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 19.1M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MDCX | CALC |
|---|---|---|
| Price | $0.31 | $0.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.50 | $10.00 |
| AVG Volume (30 Days) | ★ 1.5M | 294.0K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.46 |
| 52 Week High | $3.05 | $7.20 |
Technical Indicators
Market Signals| Indicator | MDCX | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 44.22 |
| Support Level | $0.30 | $0.66 |
| Resistance Level | $0.36 | $0.77 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 61.76 | 12.62 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.